Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
120.27
-4.06 (-3.27%)
Oct 31, 2024, 4:00 PM EDT - Market closed
Neurocrine Biosciences Employees
Neurocrine Biosciences had 1,400 employees as of December 31, 2023. The number of employees increased by 200 or 16.67% compared to the previous year.
Employees
1,400
Change (1Y)
200
Growth (1Y)
16.67%
Revenue / Employee
$1,602,000
Profits / Employee
$275,643
Market Cap
12.18B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1,400 | 200 | 16.67% |
Dec 31, 2022 | 1,200 | 300 | 33.33% |
Dec 31, 2021 | 900 | 55 | 6.51% |
Dec 31, 2020 | 845 | 145 | 20.71% |
Dec 31, 2019 | 700 | 115 | 19.66% |
Dec 31, 2018 | 585 | 185 | 46.25% |
Dec 31, 2017 | 400 | 204 | 104.08% |
Dec 31, 2016 | 196 | 76 | 63.33% |
Dec 31, 2015 | 120 | 26 | 27.66% |
Dec 31, 2014 | 94 | 13 | 16.05% |
Dec 31, 2013 | 81 | 3 | 3.85% |
Dec 31, 2012 | 78 | 7 | 9.86% |
Dec 31, 2011 | 71 | 5 | 7.58% |
Dec 31, 2010 | 66 | 1 | 1.54% |
Dec 31, 2009 | 65 | -60 | -48.00% |
Dec 31, 2008 | 125 | -10 | -7.41% |
Dec 31, 2007 | 135 | -132 | -49.44% |
Dec 31, 2006 | 267 | -321 | -54.59% |
Dec 31, 2005 | 588 | 203 | 52.73% |
Dec 31, 2004 | 385 | 40 | 11.59% |
Dec 31, 2003 | 345 | 69 | 25.00% |
Dec 31, 2002 | 276 | 54 | 24.32% |
Dec 31, 2001 | 222 | 34 | 18.09% |
Dec 31, 2000 | 188 | 37 | 24.50% |
Dec 31, 1999 | 151 | 2 | 1.34% |
Dec 31, 1998 | 149 | 41 | 37.96% |
Dec 31, 1997 | 108 | 5 | 4.85% |
Dec 31, 1996 | 103 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Fresenius Medical Care AG | 119,845 |
Smith & Nephew | 19,081 |
Catalent | 17,800 |
Teleflex | 14,500 |
AptarGroup | 13,800 |
Medpace Holdings | 5,900 |
Bio-Techne | 3,050 |
Sarepta Therapeutics | 1,314 |
NBIX News
- 1 day ago - Neurocrine Biosciences, Inc. (NBIX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance - PRNewsWire
- 21 days ago - Neurocrine: A Buy Amid CNS Pipeline Growth And Ingrezza's Strength (Rating Upgrade) - Seeking Alpha
- 22 days ago - Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results - PRNewsWire
- 4 weeks ago - Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use - PRNewsWire
- 6 weeks ago - Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit - PRNewsWire
- 7 weeks ago - Neurocrine's experimental drug misses primary goal in schizophrenia trial - Reuters
- 7 weeks ago - Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia - PRNewsWire